Yes, you can safely increase lisinopril with a GFR of 46.6 mL/min/1.73 m²
It is safe to increase lisinopril in this patient with a GFR of 46.6 mL/min/1.73 m² (CKD Stage G3a), as this is above the threshold requiring dose reduction. According to FDA labeling, no dose adjustment is required for lisinopril when creatinine clearance is >30 mL/min 1. The KDOQI guidelines specifically state to "start at lower dose in people with GFR < 45 ml/min/1.73 m²" for RAAS antagonists 2, but this patient's GFR is above this threshold at 46.6 mL/min/1.73 m².
Key Monitoring Requirements After Dose Increase
You must check GFR, serum creatinine, and potassium within 2-4 weeks of the dose increase 3, 4, 5. This is critical because:
- Continue the medication unless creatinine rises by >30% within 4 weeks 3, 4
- Monitor for hyperkalemia, which can often be managed without stopping the ACE inhibitor 3
- Watch for symptomatic hypotension
Dosing Strategy
The FDA label recommends:
- Standard initial dose: 10 mg once daily
- Usual dosage range: 20-40 mg daily
- Maximum studied dose: 80 mg (though doses above 40 mg show minimal additional benefit) 1
Research supports that higher doses (40 mg) provide additional renoprotection compared to 20 mg in diabetic nephropathy patients, with significant reductions in albuminuria even after adjusting for blood pressure changes 6.
Important Caveats
Temporarily suspend lisinopril during:
- Intercurrent illness
- Planned IV radiocontrast administration
- Bowel preparation prior to colonoscopy
- Prior to major surgery 2, 7
Do NOT discontinue simply because GFR falls below 30 mL/min/1.73 m² - ACE inhibitors remain nephroprotective even at lower GFRs 2, 3. The KDIGO 2024 guidelines explicitly state to "continue ACEi or ARB in people with CKD even when the eGFR falls below 30 ml/min per 1.73 m²" 3, 4.
When to Reduce or Stop
Consider reducing dose or discontinuing only if:
- Serum creatinine rises >30% within 4 weeks of initiation or dose increase 3
- Symptomatic hypotension occurs
- Uncontrolled hyperkalemia despite medical management
- GFR <15 mL/min/1.73 m² with uremic symptoms 3
The bottom line: At GFR 46.6, proceed with the dose increase but ensure close monitoring of renal function and potassium within 2-4 weeks.